525
Participants
Start Date
October 17, 2018
Primary Completion Date
February 18, 2022
Study Completion Date
February 18, 2022
Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine
Pharmaceutical form: Liquid solution Route of administration : Intramuscular
Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine
Pharmaceutical form: Lyophilized powder combined with liquid component Route of administration : Intramuscular
Measles, Mumps, and Rubella Virus Vaccine Live
Pharmaceutical form: Lyophilized live virus vaccine Route of administration : Subcutaneous
Pneumococcal 13-valent Conjugate Vaccine
Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
Diphtheria, Tetanus, Pertussis (Acellular, Component) Poliomyelitis (inactivated) Vaccine, and Haemophilus influenza type b Conjugate Vaccine
Pharmaceutical form: Powder and suspension for injection Route of administration: Intramuscular
Hepatitis B Vaccine
Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
Rotavirus Vaccine, Live, Pentavalent
Pharmaceutical form: Oral solution Route of administration: Oral
Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated), and Haemophilus influenzae type b conjugate vaccine
Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
Investigational Site Number :4840001, Acapulco de Juárez
Investigational Site Number :4840003, Tlaltizapán
Investigational Site Number :6431018, Gatchina
Investigational Site Number :6431007, Saint Petersburg
Investigational Site Number :6431010, Saint Petersburg
Investigational Site Number :6431001, Saint Petersburg
Investigational Site Number :6431008, Krasnodar
Investigational Site Number :6431006, Samara
Investigational Site Number :6431004, Perm
Investigational Site Number :6431002, Yekaterinburg
Investigational Site Number :4840002, Mexico City
Sanofi Pasteur, a Sanofi Company
INDUSTRY